Interaction of nanoparticles with central nervous system and its consequences

Athira, S.S.; Prajitha, N.; Mohanan, P.V.

doi:10.5455/ajrms.20180717105137

Cited by 15 publications

(13 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nanotechnology (NT) provides a new approach to develop alternative drug delivery treatments for all stages of Alzheimer’s disease (AD). NT uses particles with at least one dimension smaller than 100 nm, the nano particles (NPs) [ 1 ]. The International Organization for Standardization defines NPs as nano-objects with all three external dimensions in the nanoscale [ 2 ].…”

Section: Nanotechnology For Alzheimer’s Disease Therapymentioning

confidence: 99%

See 1 more Smart Citation

Nanotechnology Therapy for Alzheimer′s Disease Memory Impairment Attenuation

Ribarič

2021

IJMS

View full text Add to dashboard Cite

Currently, there is no cure for Alzheimer’s disease (AD) in humans; treatment is symptomatic only. Aging of the population, together with an unhealthy diet and lifestyle, contribute to the steady, global increase of AD patients. This increase creates significant health, societal and economical challenges even for the most developed countries. AD progresses from an asymptomatic stage to a progressively worsening cognitive impairment. The AD cognitive impairment is underpinned by progressive memory impairment, an increasing inability to recall recent events, to execute recently planned actions, and to learn. These changes prevent the AD patient from leading an independent and fulfilling life. Nanotechnology (NT) enables a new, alternative pathway for development of AD treatment interventions. At present, the NT treatments for attenuation of AD memory impairment are at the animal model stage. Over the past four years, there has been a steady increase in publications of AD animal models with a wide variety of original NT treatment interventions, able to attenuate memory impairment. NT therapy development, in animal models of AD, is faced with the twin challenges of the nature of AD, a chronic impairment, unique to human, of the tau protein and A β peptides that regulate several key physiological brain processes, and the incomplete understanding of AD′s aetiology. This paper reviews the state-of-the-art in NT based treatments for AD memory impairment in animal models and discusses the future work for translation to the successful treatment of AD cognitive impairment in human.

show abstract

Section: Nanotechnology For Alzheimer’s Disease Therapymentioning

confidence: 99%

“…NPs can be used either for disease diagnosis or for treatment. They can bind with a wide variety of desired ligands (by adsorbing, entrapping or covalent bonding) to acquire new diagnostic, therapeutic or physiological properties, including the ability to cross the blood-brain barrier (BBB) [ 1 ].…”

Section: Nanotechnology For Alzheimer’s Disease Therapymentioning

confidence: 99%

Nanotechnology Therapy for Alzheimer′s Disease Memory Impairment Attenuation

Ribarič

2021

IJMS

View full text Add to dashboard Cite

show abstract

“…The advent of engineered tunable NPs, with sizes in the magnitude of a billionth of a meter, has opened doors to possible therapeutic applications and proposed as a novel approach, to solving the unaddressed problem of improving the transport of biologically active substances across the BBB [ 12 , 112 ]. NPs, being in the scale of 1 and 100 nm, possess peculiar physico-chemical properties with the capacity for modification [ 14 ].…”

Section: Nanoparticle-based Cns Theranosticsmentioning

confidence: 99%

Nanoparticle-Based Technology Approaches to the Management of Neurological Disorders

Sim

Tarini

Dheen

et al. 2020

IJMS

View full text Add to dashboard Cite

Neurological disorders are the most devastating and challenging diseases associated with the central nervous system (CNS). The blood-brain barrier (BBB) maintains homeostasis of the brain and contributes towards the maintenance of a very delicate microenvironment, impairing the transport of many therapeutics into the CNS and making the management of common neurological disorders such as Alzheimer’s disease (AD), Parkinson’s disease (PD), cerebrovascular diseases (CVDs) and traumatic brain injury (TBI), exceptionally complicated. Nanoparticle (NP) technology offers a platform for the design of tissue-specific drug carrying systems owing to its versatile and modifiable nature. The prospect of being able to design NPs capable of successfully crossing the BBB, and maintaining a high drug bioavailability in neural parenchyma, has spurred much interest in the field of nanomedicine. NPs, which also come in an array of forms including polymeric NPs, solid lipid nanoparticles (SLNs), quantum dots and liposomes, have the flexibility of being conjugated with various macromolecules, such as surfactants to confer the physical or chemical property desired. These nanodelivery strategies represent potential novel and minimally invasive approaches to the treatment and diagnosis of these neurological disorders. Most of the strategies revolve around the ability of the NPs to cross the BBB via various influx mechanisms, such as adsorptive-mediated transcytosis (AMT) and receptor-mediated transcytosis (RMT), targeting specific biomarkers or lesions unique to that pathological condition, thereby ensuring high tissue-specific targeting and minimizing off-target side effects. In this article, insights into common neurological disorders and challenges of delivering CNS drugs due to the presence of BBB is provided, before an in-depth review of nanoparticle-based theranostic strategies.

show abstract

“…Recently, it has been indicated that iron nanoparticles have excellent neuroprotective effects and can raise the physiological function of the central nervous system . In many researches have been reported that FeNPs with affecting the nerve conduction and synaptic transmissions, decreasing the neural inflammation and apoptosis, increasing the neural antioxidant responses, and infiltrating immune cell, apply the excellent neuroprotective effects against several neurotoxins …”

Section: Introductionmentioning

confidence: 99%

“…[7] In many researches have been reported that FeNPs with affecting the nerve conduction and synaptic transmissions, decreasing the neural inflammation and apoptosis, increasing the neural antioxidant responses, and infiltrating immune cell, apply the excellent neuroprotective effects against several neurotoxins. [8,9] Methadone is a synthetic, long-acting opioid with pharmacologic actions qualitatively similar to morphine and is active by oral and parenteral routes of administration. It is primarily a μ-receptor agonist and may mimic endogenous opioids, enkephalins, and endorphins and affect the release of other neurotransmitters, acetylcholine, norepinephrine, substance P, and dopamine.…”

Section: Introductionmentioning

confidence: 99%

Suppressor capacity of iron nanoparticles biosynthesized using Salvia chloroleuca leaf aqueous extract on methadone‐induced cell death in PC12: Formulation a new drug from relationship between the nanobiotechnology and neurology sciences

Ahmeda

Zangeneh

Mansooridara

et al. 2020

Applied Organom Chemis

View full text Add to dashboard Cite

Metallic nanoparticles have gained significant attention in the area of biomedical technology. Because of its high surface area, metallic nanoparticles are being widely used in various fields including the medical and engineering sciences. One of the valuable applications of metallic nanoparticles especially copper, zinc, and iron nanoparticles is increasing the physiological function of central nervous system. Besides, Iranian people are using the Salvia chloroleuca for neuroprotective properties. In the present research, iron nanoparticles were biosynthesized by S. chloroleuca leaf aqueous extract as reducing and stabilizing agents. Also, we revealed the protective effect of FeNPs in methadone‐treated PC12 cells. FeNPs were characterized and analyzed using common nanotechnology techniques including FT‐IR, UV–Vis. spectroscopy; EDS, TEM, and FE‐SEM. TEM and FE‐SEM images revealed a uniform spherical morphology for FeNPs. In the biological part of the current study, the both treatments of FeNPs significantly (p ≤ 0.01) reduced the cell cytotoxicity and cell death index as well as increased the cell viability and cell proliferation in methadone‐treated PC12 cells. In these treatments, mitochondrial membrane potential significantly (p ≤ 0.01) increased compared to methadone‐induced PC12 cells. DPPH free radical scavenging test was did to evaluate the antioxidant potentials of FeCl3, S. chloroleuca, and FeNPs. DPPH test indicated similar antioxidant activities for S. chloroleuca, FeNPs, and butylated hydroxytoluene. In current experiment, we concluded that iron nanoparticles biosynthesized by S. chloroleuca leaf aqueous extract suppressed methadone‐induced cell death in a dose‐dependent manner in PC12 cells.

show abstract

Interaction of nanoparticles with central nervous system and its consequences

Cited by 15 publications

References 0 publications

Nanotechnology Therapy for Alzheimer′s Disease Memory Impairment Attenuation

Nanotechnology Therapy for Alzheimer′s Disease Memory Impairment Attenuation

Nanoparticle-Based Technology Approaches to the Management of Neurological Disorders

Suppressor capacity of iron nanoparticles biosynthesized using Salvia chloroleuca leaf aqueous extract on methadone‐induced cell death in PC12: Formulation a new drug from relationship between the nanobiotechnology and neurology sciences

Contact Info

Product

Resources

About